Pharma’s manufacturing reconfigurations provide CDMOs with expansion opportunities - Pharmaceutical Technology

Manufacturing deals saw an unusual burst of recent activity, with a spike in the number of CDMOs acquiring facilities from pharma companies. A spike in facility sales to outsourcing companies points to an industry need for greater flexibility. GSK was another of the pharma companies announcing billion-dollar manufacturing investments in the US in 2025. Credit: MAXSHOT.PL / Shutterstock.com. Manufacturing deals saw an unusual burst of activity recently, with a spike in the number of contract development and manufacturing organisations (CDMOs) acquiring facilities from pharma companies. These were led by Samsung Biologics, which completed its acquisition of a Rockville, US, manufacturing…

Source: Pharmaceutical Technology